Meeting
2018 ASCO Annual Meeting
Duration of extended adjuvant therapy with neratinib in early‑stage HER2+ breast cancer after trastuzumab-based therapy: Exploratory analyses from the phase III ExteNET trial.
Authors
Michael Gnant
Comprehensive Cancer Centre, Medical University of Vienna, Vienna, Austria
Michael Gnant , Hiroji Iwata , Anna Elizabeth Bashford , Robert Separovic , Adolfo Murias , Elena Vicente , Julie Ann Means-Powell , Ingrid A. Mayer , Francis Mark Senecal , Rina Hui , Richard H. De Boer , Joanne Chiu , Anne Armstrong , Amparo Ruiz , Richard Bryce , Yining Ye , Arlene Chan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Clinical Trial Registration Number
NCT00878709
Citation
J Clin Oncol 36, 2018 (suppl; abstr 524)
DOI
10.1200/JCO.2018.36.15_suppl.524
Abstract #
524
Poster Bd #
16
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Timing of initiation of neratinib after trastuzumab-based adjuvant therapy in early‑stage HER2+ hormone receptor (HR)-negative breast cancer: Exploratory analyses from the phase III ExteNET trial.
First Author: Bent Ejlertsen
Poster
2015 Breast Cancer Symposium
Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.
First Author: Arlene Chan
Poster
2021 ASCO Annual Meeting
Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.
First Author: Beverly Moy
Poster
2021 ASCO Annual Meeting
A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.
First Author: Snehal Patel